MedTrace Logo

Omega-3 vs Very Low Calorie Diet for Liver Size Reduction

NCT03132662 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-03-22

No results posted yet for this study

Summary

A recent review demonstrated that Non-alcoholic fatty liver disease (NAFLD) affects 10-35% of the adult population worldwide, with the prevalence approaching 85-100% in obese populations. Current standard treatment for liver reduction before surgery is the use of a very low calorie liquid diet (VLCLD). Multiple studies have shown that a 2-4 week diet with a VLCD will reduce liver volume, in preparation for surgery. Omega-3 (Ω-3) polyunsaturated fatty acids (PUFAs) have been suggested as a treatment for NAFLD. The primary aim of this study is to compare Ω-3 PUFAs and a VLCLD and their effect on left lobe live size before bariatric surgery.

Conditions

  • Obesity, Morbid
  • Obesity
  • NAFLD
  • NASH - Nonalcoholic Steatohepatitis

Interventions

DIETARY_SUPPLEMENT

Omega-3

3 gr/day of Omega-3

DIETARY_SUPPLEMENT

Very Low Calorie Diet

4 servings/day Optifast

Sponsors & Collaborators

Principal Investigators

  • Dennis Hong, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-07-01
Completion
2019-12-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03132662 on ClinicalTrials.gov